

IN THE CLAIMS:

Please cancel claim 30, and amend claims 22-29, and add new claim 31, as follows:

Claims 1-21 (canceled).

22. (currently amended)      ~~Use of a cyclosporin in association~~ A method for preparing an aqueous formulation for topical ophthalmic use comprising the step of associating a cyclosporin with hyaluronic acid or one of its salts and polysorbate 80 ~~for the preparation of a formulation in the form of an aqueous solution intended for topical ophthalmic use.~~

23. (currently amended)      Use The method for preparing an aqueous formulation according to claim 22, wherein the formulation comprises 0.02 to 2 % by weight of cyclosporin, 0.01 to 2 % by weight of hyaluronic acid or one of its salts, and 0.5 to 40 % by weight of polysorbate 80, based on the formulation's total weight.

24. (currently amended)      Use The method for preparing an aqueous formulation according to claim 22, wherein the cyclosporin is a cyclosporin A.

25. (currently amended)      Use The method for preparing an aqueous formulation according to claim 22, wherein the hyaluronic acid or its salt has a weight-average molecular weight not inferior to 1,300,000 daltons.

26. (currently amended) Use The method for preparing an aqueous formulation according to claim 25, wherein the hyaluronic acid or its salt has a weight-average molecular weight situated in the region from 1,300,000 to 3,000,000 daltons.

27. (currently amended) Use The method for preparing an aqueous formulation according to claim 22, wherein the hyaluronic acid is present as alkali metal or alkaline-earth metal hyaluronate.

28. (currently amended) Use The method for preparing an aqueous formulation according to claim 27, wherein the hyaluronic acid is present as sodium hyaluronate.

29. (currently amended) Use A method for treating conditions selected from the group consisting of keratoconjunctivitis sicca (KCS), Sjögren's syndrome, dry-eye syndrome and chronic vernal keratoconjunctivitis comprising the step of administering of a formulation comprising of a cyclosporin, hyaluronic acid or one of its salts, and polysorbate 80 for the treatment of conditions selected from the group consisting of keratoconjunctivitis sicca (KCS), Sjögren's syndrome, dry-eye syndrome and chronic vernal keratoconjunctivitis.

30. (canceled).

31. (new): A method for post-operative prophylactic treatment in keratoplasty comprising the step of using a formulation comprising a cyclosporin, hyaluronic acid or one of its salts, and polysorbate 80.